CSL Limited (ASX:CSL)
Australia · Delayed Price · Currency is AUD | Market Cap | 62.31B -46.8% |
| Revenue (ttm) | 23.10B +1.2% |
| Net Income | 2.09B -49.2% |
| EPS | 4.29 -49.5% |
| Shares Out | 479.32M |
| PE Ratio | 30.31 |
| Forward PE | 13.04 |
| Dividend | 4.09 (3.15%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | 1,616,679 |
| Average Volume | 1,250,299 |
| Open | 129.00 |
| Previous Close | 129.00 |
| Day's Range | 127.75 - 130.99 |
| 52-Week Range | 127.75 - 275.79 |
| Beta | 0.22 |
| RSI | 30.73 |
| Earnings Date | Aug 18, 2026 |
About CSL Limited
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascul... [Read more]
Financial Performance
In fiscal year 2025, CSL Limited's revenue was $15.56 billion, an increase of 5.12% compared to the previous year's $14.80 billion. Earnings were $3.00 billion, an increase of 13.63%.
Financial numbers in USD Financial StatementsNews
CSL announces expansion of Illinois plasma therapy manufacturing facility
New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018 Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies a...
CSL Limited Earnings Call Transcript: H1 2026
First half revenue and profit declined due to policy changes, one-off costs, and impairments, but strong cash flow and cost savings supported an expanded share buyback. Guidance is maintained, with second half growth expected from IG, albumin, and new products, while competitive and regulatory headwinds persist.
Deutsche Bank Appointed as Successor Depositary Bank for the American Depositary Receipt Program of CSL Limited
NEW YORK--(BUSINESS WIRE)--Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. CSL Limited (OTC: CSLLY) is ...
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit- ...
CSL Limited Transcript: CMD 2025 Part 2
Management is focused on restoring credibility and driving shareholder returns through operational efficiency, innovation, and disciplined capital allocation. IG remains the core growth driver, with high single-digit growth expected, while new products and cost-saving initiatives support robust, sustainable performance.
CSL Limited Transcript: CMD 2025 Part 1
Influenza market complexity enables strategic differentiation, with growth driven by advanced vaccine technologies and a customer-focused approach. U.S. immunization rates are down, but recovery is expected to accelerate growth, especially with new products like aTIVc and international expansion.
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing BROADMEADOWS, AUSTRALIA , Oct. 26, ...
CSL Limited Transcript: AGM 2025
FY2025 saw solid revenue and profit growth, but outlooks were revised down due to U.S. flu vaccine and China Albumin headwinds. Board changes, cost-saving initiatives, and a postponed Seqirus demerger were key topics, with shareholder concerns on remuneration and market confidence addressed.
Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines
Real-world evidence (RWE) data estimate 19.8% relative vaccine effectiveness (rVE) of cell-based quadrivalent influenza vaccines (QIVc) versus standard egg-based quadrivalent vaccines (QIVe) in the pr...
CSL Limited Earnings Call Transcript: H2 2025
Group revenue grew 5% and NPAT rose 17% year-over-year, with all business units contributing to growth. Major transformation initiatives, including $500M+ in cost savings and a planned Seqirus demerger, are underway. FY2026 guidance anticipates 4%-5% revenue growth and 7%-10% NPATA growth.
Australian biopharma firm CSL posts 14% rise in annual profit
Australian biopharmaceutical company CSL reported 14% rise in annual earnings on Tuesday, driven by strong performance at its blood plasma business CSL Behring.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start
ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and a l...
CSL Limited Transcript: Life Sciences Investor Forum
A global biotech leader reported solid H1 FY25 results, driven by strong growth in rare disease therapies and ongoing innovation in plasma and vaccine businesses. Strategic investments, operational efficiencies, and disciplined capital management position the company for sustainable long-term growth.
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3 NICE's recommendation is based on clinically meani...
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation f...
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
ANDEMBRY® is a first-in-class monoclonal antibody treatment that inhibits activated Factor XII (FXIIa), the initiating factor in the HAE pathway, and offers the first pre-filled pen presentation enabl...
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA...
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
- ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits plasma protein factor XIIa, which initiates the cascade of events leading to a...
CSL Limited Earnings Call Transcript: H1 2025
First half FY2025 saw 5% revenue growth to $8.5B and 7% NPAT growth, led by strong Behring and Vifor performance. Seqirus faced U.S. headwinds but expects H2 recovery from pandemic contracts. FY2025 guidance for 10%-13% NPATA growth is reaffirmed.
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
94 percent of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatment Mean factor IX activity levels were sustained at near normal level...
CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)
If approved, garadacimab will be the first and only once-monthly treatment inhibiting factor XIIa to prevent attacks in HAE patients – a community CSL has been serving for more than 40 years MARBURG, ...
CSL Limited Transcript: AGM 2024
The AGM highlighted strong financial growth, a robust dividend, and ongoing global expansion, while addressing challenges with the Vifor acquisition and shareholder concerns on remuneration. Strategic investments in R&D, sustainability, and talent were emphasized, with double-digit earnings growth reaffirmed for the medium term.
CSL Limited Transcript: Investor Update
The update highlights a robust, patient-focused R&D pipeline with key products nearing regulatory milestones, ongoing innovation in plasma and vaccine platforms, and strategic portfolio management. Setbacks in some late-stage trials are offset by new indications and strong progress in digital, manufacturing, and partnership initiatives.